Introduction
============

Metabolic syndrome (MetS), a clustering of cardiovascular risk factors such as insulin resistance, hypertension, glucose intolerance, hypertriglyceridemia, and low high-density lipoprotein (HDL) cholesterol levels, is a major worldwide public health problem\[[@B1]\]. The prevalence of MetS is increasing in China because of the westernization of the lifestyle, such as a high-fat and high-calorie diet and less physical activity. A recent epidemiological study indicated that the prevalence of MetS among Chinese men and women aged 35 to 64 years was 9.8% and 17.8%, respectively\[[@B2]\].

Uric acid is the end product of purine metabolism in humans. Excess serum accumulation can lead to various diseases, and most notably uric acid is causally involved in the pathogenesis of gouty arthritis \[[@B3]-[@B5]\]. Recent studies have suggested that hyperuricemia is a risk factor for cardiovascular disease (CVD) in the general population \[[@B6]-[@B8]\]. However, despite the clinical and epidemiological evidence, some authorities have considered that the association was confounded by other well-established risk factors for CVD \[[@B3],[@B9]\].

Recently, growing evidence demonstrates that uric acid may have a key role in the pathogenesis of MetS \[[@B10]\]. Recent studies in animals models report that uric acid may play a causal role in the development of MetS and decreasing uric acid levels can prevent or reverse features of the MetS \[[@B11]\].

Although previous studies have analyzed the independence of the relationship between uric acid and MetS and carotid atherosclerosis, thus far, few have examined in type 2 diabetes and there is a scarcity of data evaluating the effect of MetS on the association between serum uric acid and carotid atherosclerosis. In this study, we aimed to investigate the association between the serum uric acid and MetS and carotid atherosclerosis in patients with type 2 diabetes.

Methods
=======

Study subjects
--------------

A cross-sectional study to evaluate the prevalence of diabetic complications in Chinese patients aged over 30 and diagnosed with type 2 diabetes was planned in downtown Shanghai. The details of the study design have been described previously\[[@B12]\]. In brief, the study was conducted from February to July 2004. 20 residential areas administered by 20 residents\' committees were sampled randomly in the central area of Shanghai. Questionnaires to identify diabetes history were sent to every household in the 20 residential areas and collected by primary care clinicians and endocrinologists. A total of 1120 Chinese patients diagnosed with type 2 diabetes were identified via the questionnaire. Finally, 1039 Chinese patients diagnosed with type 2 diabetes were enrolled in our study. After excluding those who did not have serum uric acid data (n = 13), 1026 individuals (395 men and 631 women) were eligible for the present analysis. The study was approved by the Institution Review Board of the Huashan Hospital, and written informed consents were obtained from all participants.

Laboratory measurements
-----------------------

Overnight fasting blood samples were collected in tubes containing liquid EDTA, centrifuged at 4°C, and stored at -80°C until analysis. The measurements of total cholesterol, HDL-cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, insulin, creatinine, and C-reactive protein (CRP) were previously described\[[@B12],[@B13]\]. Insulin resistance was estimated using homeostasis model assessment index-insulin resistance (HOMA-IR) \[[@B14]\]. A sterile, random-spot urine sample was used to measure the albumin/creatinine ratio (ACR). We used the modification of diet in renal disease (MDRD) equation re-calibrated for Chinese to estimate eGFR expressed in ml/min/1.73 m^2^: eGFR = 186 × \[SCR × 0.011\]^-1.154^× \[age\]^-0.203^× \[0.742 if female\] × 1.233, where SCR is serum creatinine expressed as μmol/l and 1.233 is the coefficient for Chinese.

Carotid ultrasonography
-----------------------

Carotid ultrasonography was performed using an Acuson Sequoia 512. Trained and certified sonographers conducted the examination. The ultrasound scanning protocol in our study was modified in terms of procedures used in previous studies \[[@B15]-[@B17]\]. Computer-assisted edge-detection software was not used for measurement of carotid intima-media thickness (IMT). A lateral view of bilateral images of common carotid arteries (1 cm proximal to the dilatation of the carotid bulb), carotid bulb (identified by the loss of the parallel wall present in the common carotid artery) and internal carotid artery (1 cm distal to the tip of the flow divider that separates the external and internal carotid arteries) was obtained. Sonographers recorded the images and completed ultrasound readings. IMT is the distance between the lumen-intima interface and the media-adventitia interface \[[@B18]\]. Common carotid artery IMT was defined as the mean of the maximum IMT in both right and left sides of common carotid artery.

The plaque of carotid artery (common carotid artery, carotid bulb and internal carotid artery) is defined as a localized protrusion of the internal part of the vessel wall into the lumen of 50% of the surrounding IMT value. Plaque presence was defined as ≥1 plaque in any of the carotid arteries \[[@B19]\].

Definition of MetS
------------------

The MetS was defined based on the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian-Americans\[[@B20]\]: (1) as presenting at least three of the following components: 1) waist circumferences 90 cm or greater in men or 80 cm or greater in women; 2) triglycerides 1.7 mmol/liter or greater; 3) HDL cholesterol less than 1.03 mmol/liter in men or less than 1.30 mmol/liter in women; 4) blood pressure 130/85 mm Hg or greater or current use of antihypertensive medications; or 5) fasting plasma glucose (FPG) 5.6 mmol/liter or greater or previously diagnosed type 2 diabetes or on oral antidiabetic agents or insulin.

Statistical analysis
--------------------

Normally distributed data were expressed as means ± SD, whereas variables with a skewed distribution were reported as median (interquartile range) and log transformed to approximate normality before analysis. Categorical variables were represented by frequency and percentage. Analysis of covariance for continuous variables and multivariate logistic regression analysis for categorical variables were applied for the comparison according to uric acid quartiles. Analysis of covariance was used to compare uric acid levels between genders. Correlation coefficients between uric acid and metabolic features were calculated by partial correlation analysis on ranks (Spearman correlation). Serum uric acid levels were depicted according to the number of MetS components using linear regression model. Multivariate logistic regression models were used to estimate the odds ratios (ORs) for MetS. Potential confounding variables including age, gender, smoking, alcohol drinking, self-reported CVD, family history of diabetes, eGFR, HbA~1C~, CRP, HOMA-IR and body mass index (BMI) were controlled in the regression models. Data management and statistical analysis were performed using SPSS version 13.0 for Windows (SPSS, Chicago, IL, USA). P \< 0.05 was considered statistically significant.

Results
=======

Characteristics of participants according to serum uric acid quartiles
----------------------------------------------------------------------

We identified 1026 patients with type 2 diabetes with a mean age of 65.57 ± 11.70 years. At the time of uric acid determination, history of hypertension was documented in 761 patients (74.2%) and CVD in 200 patients (19.5%). Baseline demographic and medical characteristics for both genders combined and divided by uric acid quartiles are illustrated in Table [1](#T1){ref-type="table"}. When analyzed by quartiles of uric acid levels, the patients with higher uric acid were more likely to be male and smokers (both P \< 0.05). With respect to metabolic parameters, the patients in the higher uric acid quartiles exhibited higher levels of systolic blood pressure, BMI, waist circumference, HOMA-IR, CRP, IMT, creatinine, ACR and triglycerides (all P \< 0.05). In contrast, the patients with higher uric acid levels displayed shorter duration of diabetes and lower levels of FPG, HbA~1C~, eGFR and HDL cholesterol (all P \< 0.001).

###### 

Characteristics of study participants according to uric acid quartiles^a^

  -----------------------------------------------------------------------------------------------------------------------------
  Characteristics                 Q1\                 Q2\                  Q3\                  Q4\                  *P*value
                                  (n = 256)\          (n = 257)\           (n = 256)\           (n = 257)\           
                                  \<230               231-280              281-330              ≥331                 
  ------------------------------- ------------------- -------------------- -------------------- -------------------- ----------
  MetS (%)                        20.3                35.8                 54.3                 84.8                 \<0.001

                                                                                                                     

  Uric acid (μmol/L)              200 (190-220)       260 (250-270)        310 (300-320)        390 (350-430)        \<0.001

  Age (yr)^b^                     65.28 ± 11.27       66.57 ± 10.28        65.09 ± 12.35        67.52 ± 11.84        0.065

  Male^b^                         73 (28.29)          91 (30.33)           92 (41.81)           139 (56.05)          \<0.001

  Smoking (yes)                   47 (18.22)          47 (15.67)           52 (23.64)           63 (25.40)           0.017

  Alcohol (yes)                   27 (10.47)          27 (9.00)            31 (15.50)           38 (15.32)           0.084

  Duration of diabetes (yr)       9.72 ± 7.84         7.74 ± 7.04          7.24 ± 6.69          6.75 ± 6.56          \<0.001

  Self-reported CVD^c^            49 (18.99)          62 (20.67)           49 (22.27)           59 (23.79)           0.587

  Family history of diabetes^d^   112 (43.41)         119 (39.67)          74 (33.64)           84 (33.87)           0.068

  SBP (mmHg)                      138.44 ± 20.68      139.92 ± 19.82       140.86 ± 22.00       142.31 ± 20.05       \<0.001

  DBP (mmHg)                      80.71 ± 10.54       82.57 ± 10.92        82.14 ± 12.18        82.38 ± 10.69        0.207

  BMI (kg/m^2^)                   24.21 ± 3.39        24.91 ± 3.23         25.40 ± 3.47         25.97 ± 3.39         \<0.001

  Waist circumference (cm)        81.74 ± 9.68        83.62 ± 8.50         86.05 ± 9.32         87.67 ± 8.88         \<0.001

  Waist to hip ratio              0.86 ± 0.08         0.87 ± 0.06          0.88 ± 0.06          0.89 ± 0.06          0.176

  Glucose (mmol/L)                9.25(7.20-12.30)    7.70(6.40-9.60)      7.80(6.60-9.70)      7.30(6.23-8.80)      \<0.001

  Insulin (μU/mL)^e^              9.93 (5.85-15.06)   11.06 (6.93-17.26)   12.40 (7.93-18.24)   13.19 (8.80-20.13)   0.143

  HOMA-IR^e^                      3.91 (2.28-6.70)    3.98 (2.36-7.21)     4.40 (2.62-7.38))    4.44 (2.63-6.55      0.028

  CRP                             1.92 (0.95-4.35)    1.98 (0.71-4.92)     2.33 (0.73-5.24)     3.59 (0.81-8.87)     \<0.001

  IMT (mm)                        0.82 ± 0.21         0.85 ± 0.22          0.86 ± 0.26          0.93 ± 0.29          0.016

  HbA~1C~(%)                      7.91 ± 1.94         7.10 ± 1.59          6.96 ± 1.42          6.93 ± 1.36          \<0.001

  Creatinine (μmol/L)             60.67 ± 13.14       65.22 ± 19.63        67.35 ± 15.50        81.09 ± 28.75        \<0.001

  eGFR (ml/min/1.73^2^)           132.5 ± 25.5        125.2 ± 25.4         122.5 ± 26.7         108.3 ± 31.2         \<0.001

  ACR (mg/mmol)                   2.45 (1.25-6.04)    2.80 (1.35-9.59)     3.02 (1.54-8.11)     3.52 (1.74-8.94)     0.022

  Triglycerides (mmol/L)^e^       1.41 (0.97-1.91)    1.56 (1.09-2.23)     1.67 (1.17-2.41)     1.84 (1.28-2.64)     \<0.001

  Total cholerterol (mmol/L)      5.32 ± 0.07         5.37 ± 0.07          5.44 ± 0.08          5.33 ± 0.07          0.623

  LDL cholesterol (mmol/L)        2.99 ± 0.90         3.04 ± 0.84          3.11 ± 0.86          3.07 ± 0.85          0.189

  HDL cholesterol (mmol/L)        1.47 ± 0.40         1.37 ± 0.36          1.26 ± 0.35          1.14 ± 0.29          \<0.001
  -----------------------------------------------------------------------------------------------------------------------------

SBP, systolic blood pressure; DBP, diastolic blood pressure.; IMT, intima-media thickness

^a^Data are means SD, median (interquartile range), or number (percent); P value was calculated after adjustment for age, gender.

^b^Not adjusted for itself.

^c^Self-reported CVD including stroke and coronary heart disease.

^d^Parents or siblings had a history of diabetes.

^e^These variables were log transformed before analysis.

Association between serum uric acid and MetS
--------------------------------------------

Partial correlation analysis demonstrated strong correlation between uric acid and BMI, waist circumference, HOMA-IR, CRP, TG and HDL cholesterol among various metabolic features (Table [2](#T2){ref-type="table"}).

###### 

Correlation between serum uric acid and other parameters in patients with type 2 diabetes^a^

  Variable               Correlation coefficient   P value
  ---------------------- ------------------------- ---------
  Age                    0.04                      0.19
  BMI                    0.15                      \<0.001
  Duration of diabetes   -0.14                     \<0.001
  Waist circumference    0.21                      \<0.001
  Waist to hip ratio     0.08                      0.01
  SBP                    0.04                      0.23
  DBP                    0.02                      0.48
  CRP                    0.08                      0.01
  Glucose                -0.26                     \<0.001
  Insulin                0.11                      \<0.001
  HbA~1C~                -0.24                     \<0.001
  HOMA-IR                0.07                      0.02
  IMT                    0.07                      0.02
  Creatinine             0.33                      \<0.001
  eGFR                   -0.36                     \<0.001
  ACR                    0.11                      \<0.001
  Triglycerides          -0.04                     0.20
  Total cholesterol      0.20                      \<0.001
  LDL cholesterol        0.01                      0.80
  HDL cholesterol        -0.33                     \<0.001

IMT, intima-media thickness; SBP, systolic blood pressure; DBP, diastolic blood pressure;

^a^All correlation coefficients were calculated after adjustment for age, gender.

Remarkably, serum uric acid levels increased gradually with increasing number of MetS components (Figure [1](#F1){ref-type="fig"}). The mean values (SE) of uric acid concentrations significantly increased for those with one to five components were 246.67 (7.89), 268.31 (4.37), 277.91 (4.28), 303.35 (4.56), and 330.35 (6.70) μmol/L, respectively, after adjustment for age, gender, creatinine, alcohol drinking, smoking, duration of diabetes, self-reported CVD and family history of diabetes.

![**Plasma uric acid levels according to the number of MetS components**. Data are shown as means ± SE after adjustment for age, gender, eGFR, alcohol drinking, smoking, duration of diabetes, self-reported CVD, and family history of diabetes; P \< 0.001 for trend.](1475-2840-10-72-1){#F1}

As presented in Table [3](#T3){ref-type="table"}, the ORs for MetS were higher with increasing uric acid quartiles (P \< 0.001 for trend). In the highest uric acid quartile, the ORs were 3.97 \[95% confidence interval (CI) 2.58-6.13\] for MetS after adjusting for age, gender, creatinine, alcohol drinking, smoking, duration of diabetes and family history of diabetes.

###### 

Adjusted ORs and 95% CIs for MetS and carotid plaque according to uric acid quartiles

                   ORs (95% CI)   P value for trend                                         
  ---------------- -------------- ------------------- ------------------ ------------------ ---------
  MetS                                                                                      
  Model 1^a^       1.0            1.42 (0.99-2.04)    2.27 (1.51-3.42)   3.97 (2.58-6.13)   \<0.001
  Model 2^b^       1.0            1.37 (0.95-1.98)    2.21 (1.44-3.39)   3.65 (2.33-5.71)   \<0.001
  Model 3^c^       1.0            1.33 (0.88-2.07)    2.27 (1.36-3.71)   3.77 (2.26-6.29)   \<0.001
  Model 4^d^       1.0            1.22 (0.82-1.83)    1.93 (1.22-3.03)   3.26 (2.03-5.25)   \<0.001
  carotid plaque                                                                            
  Model 1\*        1.0            1.33 (0.88-1.89)    1.89 (1.16-2.85)   2.71 (1.62-4.47)   0.013
  Model 2^†^       1.0            1.29 (0.82-1.81)    1.82 (1.13-2.77)   2.53 (1.49-4.13)   0.019
  Model 3^‡^       1.0            1.22 (0.81-1.85)    1.68 (1.12-2.58)   2.42 (1.40-3.75)   0.020
  Model 4^ξ^       1.0            1.18 (0.80-1.76)    1.52 (1.04-2.50)   2.21 (1.32-3.49)   0.036

^a^Model 1 adjusted for age and gender.

^b^Model 2 further adjusted for alcohol drinking, smoking, duration of diabetes, and family history of diabetes.

^c^Model 3 further adjusted for eGFR, CRP, HbA~1C~and HOMA-IR.

^d^Model 4 further adjusted for BMI.

\*Model 1 adjusted for age and gender.

^†^Model 2 further adjusted for alcohol drinking, smoking, duration of diabetes, and family history of diabetes.

^‡^Model 3 further adjusted for eGFR, CRP, HbA~1C~and HOMA-IR.

^ξ^Model 4 further adjusted for BMI and MetS.

Association between serum uric acid and carotid atherosclerosis
---------------------------------------------------------------

Partial correlation analysis demonstrated a significant correlation between uric acid and IMT (p = 0.02) (Table [2](#T2){ref-type="table"}).

As presented in Table [3](#T3){ref-type="table"}, the ORs for carotid atherosclerotic plaques (PLQ) were higher with increasing uric acid quartiles (p = 0.013 for trend). In the highest uric acid quartile, the ORs were 2.71 \[95% confidence interval (CI) 1.62-4.47\] for PLQ after adjusting for age, gender, eGFR, alcohol drinking, smoking, duration of diabetes and family history of diabetes.

Effect of MetS on the association between serum uric acid and PLQ
-----------------------------------------------------------------

After adjusting for age, gender, eGFR, alcohol drinking, smoking, duration of diabetes and family history of diabetes, MetS was associated with the PLQ with an odds ratio of 2.24 (95% CI 1.34-3.57, P \< 0.001). Thus, we next investigated the association between serum uric acid and PLQ according to the status of MetS. After adjusting for age, gender, HbA~1C~, BMI, systolic blood pressure, diastolic blood pressure, FPG, alcohol drinking, smoking, duration of diabetes and family history of diabetes, in the highest uric acid quartile, the ORs were 1.85 (95% CI 1.14-2.83, p = 0.023) for carotid plaque in subjects without MetS and 3.07 (95% CI 1.25-6.42) in subjects with MetS.

Serum uric acid level and glucose control
-----------------------------------------

Hyperglycaemia as reflected by mean HbA~1C~levels was associated with lower serum uric acid levels. As summarized in Table [1](#T1){ref-type="table"}, the patients with higher uric acid levels displayed lower HbA~1C~and fasting glucose levels (both P \< 0.001). HbA~1C~and FPG were negatively correlated with serum uric acid (Table [2](#T2){ref-type="table"}). Moreover, we also observed that serum uric acid levels were negatively related to the duration of diabetes (P \< 0.001).

Discussion
==========

In the present study, we found that serum uric acid levels showed association with the risk of MetS and carotid atherosclerosis from the cross-sectional data in type 2 diabetes. Moreover, these associations are independent of lifestyle factors, eGFR, duration of diabetes, family history of diabetes and remarkably, CRP, HbA~1C~, HOMA-IR and BMI.

Possible associations between uric acid and MetS were evaluated in some studies \[[@B10],[@B21]\]. We also observed that the ORs were substantially higher for MetS \[OR 3.97, (95% confidence interval 2.58-6.13)\] (P \< 0.001 for trend) and PLQ \[OR 2.71 (95% confidence interval 1.62-4.47)\] (p = 0.013 for trend) in the highest serum uric acid quartile compared with those in the lowest quartile. In addition, we observed the serum uric acid concentration increased monotomically with the number of MetS components (P \< 0.001 for trend). However, the underlying mechanisms of these associations are still largely unknown although much research has been done in this area. Recent studies indicate that hyperuricemia may be partially responsible for the proinflammatory endocrine imbalance in the vascular smooth muscle cells and adipose tissue, which is an underlying mechanism of the low-grade inflammation and insulin resistance in subjects with the CVD and MetS \[[@B22],[@B23]\]. Lowering uric acid in mice by allopurinol could improve the proinflammatory endocrine imbalance in the adipose tissue by reducing production of monocyte chemoattractant protein-1 (MCP-1) and increasing production of adiponectin. In addition, lowering uric acid in obese mice decreased macrophage infiltration in the adipose tissue and reduced insulin resistance \[[@B21]\]. Moreover, uric acid has also been shown to induce production of interleukin 1β, interleukin 6, tumor necrosis factor α in human mononuclear cells, and CRP in cultured human vascular cells\[[@B24]\], all these have been suggested that uric acid may have some interaction with other inflammatory cytokines. In line with views, we observed significant correlation between serum uric acid and CRP levels even after adjustment for other potential confounders (r = 0.08, p = 0.01). Furthermore, we also observed that CRP increased with serum uric acid quartiles in this study (P \< 0.001), which indicate that uric acid is correlated with low-grade systemic inflammatory response and could potentially modulate chronic inflammatory processes\[[@B25]\]. It is well-known that subclinical inflammation is a risk factor not only for MetS but also for diabetes complications such as CVD and stroke \[[@B26],[@B27]\]. Taken together, these important and intriguing results suggest that uric acid may play a causal role in the pathogenesis of atherosclerosis and the MetS partially by inflammatory pathway.

Given the serum uric acid levels were significantly associated with atherosclerosis and the MetS\[[@B28],[@B29]\], it is plausible to consider uric acid as a promising candidate for risk assessment and a potential intervention target for CVD and MetS. Interestingly, in line with our hypothesis, some studies have demonstrated that reducing uric acid by treatment with allopurinol significantly improved endothelial function, peripheral vasodilator capacity and blood flow both locally and systemically, which represent a new potential therapeutic approach \[[@B30]-[@B32]\]. Certainly, prospective studies with solid clinical end points are urgently needed to clarify whether a high uric acid level plays a causal role in the development of CVD and MetS.

One of the interesting findings of the present study is the inverse association of serum uric acid with diabetic parameters (duration of diabetes, HbA~1C~, FPG). The inverse association of serum uric acid with diabetic parameters is counterintuitive. Historically, the elevated level of uric acid observed in the MetS has been attributed to hyperinsulinemia, since hyperinsulinemia is known to be associated with impaired renal uric acid excretion and hyperuricemia in these patients are likely to be due to retention of uric acid\[[@B33]\]. But here in our current study, the type 2 diabetes patients with a higher HbA~1C~, fasting glucose and a longer duration of diabetes are likely to be accompanied by worsening function of beta cells to secrete adequate amounts of insulin. And the inverse relationship between serum uric acid and diabetic parameters (duration of diabetes, HbA~1C~, FPG) observed in these diabetic subjects may probably be caused by the increased renal excretion of uric acid in the presence of hyperglycaemia. It is well-known that with the increasing of the duration of diabetes, which is accompanied by worsening of the function of beta cells and deterioration of glycemic control, the rate of renal filtration in patients with diabetes increases gradually. The hyperfiltration state which caused by hyperglycaemia promotes the excretion of uric acid, which partly explain the existence of the inverse relationship between serum uric acid and diabetic parameters. Patients with long-term hyperfiltration state may eventually develop into diabetic nephropathy. Consistent with our hypothesis, we observed that ACR increased and eGFR decreased with serum uric acid quartiles in this study (p values were 0.022 and 3.7 × 10^-5^, respectively).

As a cross-sectional study, there are several limitations. The mechanisms underlying these associations are still to be explored. The present findings are inherently limited in the ability to eliminate causal relationships between uric acid and MetS. Although most potential confounders were carefully controlled, since some of the study patients had several risk factors including hypertension and dyslipidemia, we could not eliminate the possible effect of underlying diseases and medications used for these diseases on the present findings. Further prospective population-based trials are needed to investigate the mechanisms in order to answer these questions.

In conclusion, our data indicate that serum uric acid levels are significantly associated with MetS and carotid atherosclerosis in patients with type 2 diabetes, even after adjustment for other potential confounders. Furthermore, our findings suggest that the observed association between uric acid and carotid atherosclerosis may be attributed to metabolic syndrome-dependent and -independent mechanisms. Prospective studies are required to assess the time course and causal relevance of serum uric acid in the development of MetS and carotid atherosclerosis in patients with type 2 diabetes.
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